Menu

利伐沙班纳入医保了吗?

Author: Medicalhalo
Release time: 2025-10-19 11:44:20

Rivaroxaban, the main component of Rivaroxaban Tablets, is a highly selective oral drug that directly inhibits factor xa. After taking it, it can interrupt the endogenous and exogenous pathways of the coagulation cascade by inhibiting factor xa, and can directly inhibit thrombin generation and thrombosis. It is mostly used to treat venous thrombosis in adults. After use, it can reduce the risk of DVT recurrence and pulmonary embolism after acute deep vein thrombosis (DVT). It is used for adult patients with non-valvular atrial fibrillation who have one or more risk factors such as congestive heart failure, hypertension, diabetes, stroke or transient ischemic attack. It can help patients reduce the risk of stroke and systemic embolism. However, patients should take it symptomatically under the guidance of a doctor.

Rivaroxaban was jointly developed by Bayer and Johnson & Johnson. Its chemical name is: 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolin-5-yl)methyl)thiophene-2-carboxamide. It obtained EU marketing authorization in September 2008, and on July 1, 2011, the FDA approved the drug for the prevention of deep vein thrombosis in patients undergoing knee or hip replacement surgery. In China, rivaroxaban tablets were approved for sale by the State Food and Drug Administration in March 2009. The selling price of our juicy original drugs is relatively high. Some drugs can easily cost tens of thousands of dollars throughout the year, and many families cannot afford it. Therefore, many patients hope that rivaroxaban will be included in medical insurance to reduce the financial burden on patients. So has rivaroxaban been included in medical insurance?

It is understood that in 2009, rivaroxaban successfully entered the national medical insurance directory. Rivaroxaban belongs to Category B of the medical insurance. The insured persons will first pay a certain proportion of the expenses incurred by using this type of drug, and then it will be included in the scope of payment of the basic medical insurance fund, and the expenses will be paid in accordance with the provisions of the basic medical insurance.

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。